Glaucoma and Marijuana: Does It Help?

The duration of marijuana's IOP-lowering effect is one of the most significant limitations of using cannabis for glaucoma management.

A single dose of marijuana or THC typically lowers eye pressure for only three to four hours. After that period, IOP returns to its previous level. Because glaucoma requires consistent pressure control 24 hours a day, a patient would need to consume marijuana six to eight times daily to maintain any meaningful reduction in eye pressure.

Smoking or ingesting marijuana every three to four hours around the clock is neither practical nor safe for long-term disease management. The psychoactive effects alone would make it impossible to maintain a normal daily routine, hold a job, drive, or operate machinery. This stands in sharp contrast to modern glaucoma eye drops, many of which provide sustained pressure reduction with just one or two applications per day.

Eye pressure can fluctuate throughout the day and often rises during sleep. Controlling pressure overnight is a critical component of glaucoma management, especially for patients with ocular hypertension. Marijuana's short duration of action makes overnight control virtually impossible, as no one can consume cannabis at regular intervals while sleeping.

Researchers have attempted to develop THC-based eye drops, but no effective, commercially available product exists. THC is poorly soluble in water, making it difficult to formulate as a topical eye drop. Early attempts at topical application did not demonstrate the same IOP-lowering effect seen with smoking or ingestion. While some pharmaceutical research continues in this area, no marijuana-derived eye drop is currently approved or recommended for glaucoma treatment.

Beyond the impracticality of frequent dosing, marijuana carries risks that can undermine eye health. These include lowered systemic blood pressure that may reduce optic nerve blood flow, cognitive impairment that affects daily functioning, and the respiratory risks associated with chronic smoking. Patients who substitute marijuana for prescribed glaucoma treatments put themselves at risk for uncontrolled eye pressure and irreversible vision loss.

CBD (cannabidiol) does not appear to lower eye pressure and may actually make things worse. A 2018 study at Indiana University found that CBD applied topically to the eyes raised intraocular pressure by approximately 18% in animal models. CBD was also shown to interfere with THC's IOP-lowering mechanism when both compounds were used together. The American Academy of Ophthalmology specifically warns against using CBD for glaucoma.

The core issue is the gap between marijuana's short-lived effect and glaucoma's need for sustained, around-the-clock pressure control. A patient would need to remain intoxicated 24 hours a day to achieve even a marginal decrease in eye pressure. The side effects, including impaired cognition, reduced blood pressure, and potential harm to optic nerve blood flow, far outweigh any temporary benefit.

FDA-approved glaucoma treatments provide far more effective and consistent pressure control. Prescription eye drops such as prostaglandin analogs, beta-blockers, and alpha-adrenergic agonists can maintain lower IOP with just one or two daily applications. Laser procedures like selective laser trabeculoplasty (SLT) and surgical options including minimally invasive glaucoma surgery (MIGS) offer additional alternatives. If you are curious about other lifestyle factors, you may also want to read about caffeine and glaucoma.

No study has shown that cannabis use slows, stops, or reverses glaucoma progression over the long term. The available evidence consistently demonstrates a short-term IOP reduction lasting only a few hours, with no proof that this translates into protection of the optic nerve or preservation of the visual field. Patients who wish to explore every option for managing their glaucoma should discuss proven treatments with their eye care provider rather than relying on cannabis.